University Of Miami Miller School of Medicine: Stem Cell Studies Build Momentum toward Therapy for Age-Associated Frailty

OCTOBER 23, 2017

Buoyed by promising results of a Phase I study demonstrating the safety of mesenchymal stem cell therapy to treat frailty in older adults, researchers at the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami Miller School of Medicine have taken it a step further. Now Phase II randomized, placebo-controlled trial findings have verified […]

learn more

Miami Herald: Stem cell infusions improved health in frail elderly, UM researchers say

OCTOBER 20, 2017

Dr. Joshua Hare, director of the University of Miami’s Interdisciplinary Stem Cell Institute, conducts research in the lab at the UM Miller School of Medicine. Hare recently co-authored a study published in the Journals of Gerontology that found stem cell infusion therapy helped to improve lung function and physical ability in frail elderly patients. PATRICK FARRELL MIAMI […]

learn more

Longeveron Pioneering Development of Stem Cell Therapies for Aging Frailty

OCTOBER 17, 2017

Longeveron LLC, a leading life sciences company developing innovative therapies for age-related diseases, announced that the company is progressing with the development of its stem cell treatment to ameliorate aging frailty.  The company is building on Phase 1 safety and Phase 2 safety, tolerability and efficacy studies conducted by the University of Miami Miller School of Medicine […]

learn more

US News and World Report: Stem Cells May Hold the Fix

OCTOBER 04, 2017

Believe it or not, the cure to what ails you could already be inside you. Welcome to the dawning world of stem cell therapy, in which researchers are exploring the possibilities of growing new body parts and healing old ones by using patients’ own stem cells. The idea is that these unspecialized cells (which can […]

learn more

Longeveron Initiates Phase 2b Stem Cell Therapy Trial to Treat Aging Frailty

SEPTEMBER 07, 2017

Longeveron LLC, a regenerative medicine company developing cellular therapies, announced today that it treated its first patient in the Company’s Phase 2b clinical trial evaluating the safety and efficacy of Longeveron human Allogeneic Mesenchymal Stem Cells (LMSCs) in patients with Aging Frailty Syndrome. This trial is being conducted pursuant to an Investigational New Drug Application […]

learn more

Longeveron to Sponsor Industry Symposium on Regenerative Medicine at 2017 IAGG World Congress

JULY 21, 2017

Longeveron LLC is sponsoring a regenerative medicine symposium at the 2017 International Association of Gerontology and Geriatrics (IAGG) World Congress on July 25 in San Francisco.  The symposium, titled Regenerative Medicine Alternatives for Aging Conditions, will feature a global panel of physicians who are experts in stem cell therapy and geriatric conditions, such as Aging […]

learn more

Longeveron to Receive Grant from the Maryland Stem Cell Research Fund

MAY 22, 2017

MIAMI, Fl., May 22, 2017 – Longeveron announced receiving a $750,000 grant from the Maryland Stem Cell Research Fund (MSCRF) to continue groundbreaking stem cell research.  Longeveron, a Miami based regenerative medicine company, will partner with the University of Maryland and Johns Hopkins University to conduct a clinical trial for Hypoplastic Left Heart Syndrome (HLHS), […]

learn more

Longeveron Announces Publication of Phase 1 Safety and Efficacy Trial Results for Allogeneic Stem Cell Treatment in Frailty Patients

MAY 15, 2017

MIAMI, Fl., May 15, 2017 – Longeveron LLC, a leading regenerative medicine company developing innovative therapies for age-related diseases, announced the publication of Phase 1 safety, tolerability and efficacy data of its proprietary allogeneic mesenchymal stem cell (MSC) product in patients with Aging Frailty. The results were published on April 21st online in the Journals […]

learn more

Longeveron Begins Enrollment of Second Cohort of Phase 1 Trial of Allogeneic Mesenchymal Stem Cells to Treat Alzheimer’s Disease Patients

MAY 10, 2017

Data Monitoring Committee Confirms Safety and Recommends Trial Proceed   MIAMI, Fl., May 10, 2017 – Longeveron, a regenerative medicine company, today announced that their Phase 1 Alzheimer’s disease trial will proceed with enrollment at the recommendation of an independent Data Monitoring Committee (DMC) which reviewed data from the trial’s safety run-in phase. The clinical […]

learn more


APRIL 14, 2017

BARCELONA, SPAIN, April 28, 2017. Stem cells from healthy young donors, delivered via intravenous infusion to frail older adults, were shown to reduce inflammation in a small pilot study reported today at the International Conference on Frailty and Sarcopenia Research (ICFSR). These findings suggest that stem cells may have the potential to reverse some of […]

learn more

Longeveron is Hosting a Satellite Symposium at the IAGG 2017 in San Francisco

APRIL 03, 2017

Longeveron’s symposium will be in Tuesday July 25 during lunch and will accommodate up to 125 attendees. This will include a panel presentation with some of the world experts on frailty. The theme for IAGG 2017, “Global Aging and Health: Bridging Science, Policy, and Practice,” will convene professionals from a variety of disciplines such as […]

learn more

Longeveron will be speaking at the International Conference on Frailty and Sarcopenia Research

APRIL 03, 2017

Longeveron will be speaking at the International Conference on Frailty and Sarcopenia Research in Barcelona, Spain on April 27-29, 2017. Learn more

learn more

Researchers Testing Stem Cells To Treat Alzheimer’s

APRIL 14, 2016

By Alexandria Hein In a first-of-its-kind clinical trial, researchers at the University of Miami Miller School of Medicine are using mesenchymal stem cells (MSCs) in an attempt to slow or reverse the symptoms of Alzheimer’s disease. The team is aiming to enroll 30 patients who will be tested and observed for cognitive function, memory, quality […]

learn more


Stem Cell Transplantation for Frailty

The Journals of Gerontology, 12 October, 2017

It was reported over 50 years ago that old age is associated with depletion and loss of function of stem cells (1). Since that time, there has been extensive research confirming the deleterious effects of aging on all types of stem cells, and a growing belief that such age-related changes in stem cells further accelerate tissue and organismal aging (2–4). There are two major divisions of stem cells, embryonic stem cells and adult stem cells.

Learn More

Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty

Published by Oxford University Press on behalf of The Gerontological Society of America.

Impaired endogenous stem cell repair capacity is hypothesized to be a biologic basis of frailty. Therapies that restore regenerative capacity may therefore be beneficial. This Phase 1 study evaluated the safety and potential efficacy of intravenous, allogeneic, human mesenchymal stem cell (allo-hMSC)-based therapy in patients with aging frailty.